The MedTech arena is not the easiest to navigate with how many companies are in it. It’s all about finding emerging players like This Comapny who have successfully navigated the regulatory process (a real barrier to entry) and show real growth! The MedTech sector is often overlooked but is just as innovative as many of the top tech names. Two massive multi-billion-dollar markets for its regenerative therapies position This Stock as one of the most promising up-and-coming MedTech trades on Wall Street! 2023 was a pivotal year for this company which has established a solid foundation for the company's future expansion, which now includes a potential uplisting to a senior stock exchange! The company also recently released its 1Q2024 earnings results, which vastly exceeded estimates as revenue growth accelerated, and the company posted its FIRST quarterly profit. These stellar results have led to Zack’s Small Cap Research increasing its price target to $23.25! “We reiterate our belief that BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future,” says Zack’s. This Company is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. The market for improved wound care products is growing exponentially. In terms of revenue, the global wound care market in terms of revenue was estimated to be worth $20.8 billion in 2022 and is poised to reach $27.2 billion by 2027, growing at a CAGR of 5.4% from 2022 to 2027. The company remains committed to its mission of delivering unparalleled wound care solutions for patients and healthcare professionals, and look forward to broadening its reach into new markets this year. SEE WHY THIS HIDDEN GEM IN THE GROWING MEDTECH SPACE THAT NOW CARRIES A $23.25 ZACKS PRICE TARGET! | 
没有评论:
发表评论